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Previous studies have reported that the rate of FEV1 decline over time is increased in HIV
patients but the mechanisms underlying this observation are unclear. Since current HIV
treatment with Highly Active Antiretroviral Therapy (HAART) results in very good immune-
viral control, we hypothesized that HAART should normalize the elevated rate of FEV1
decline previously reported in HIV patients if it was somehow related to the immune alter-
ations caused by HIV, particularly in never smokers or quitters, since smoking is a well
established risk factor for accelerated FEV1 decline in the general population.
Methods
We explored this hypothesis in a prospectively recruited cohort of 188 HIV (smoker and
non-smoker) patients treated with HAART in Palma de Mallorca (Spain) and followed-up for
6 years. The cross-sectional characteristics of this cohort have been published elsewhere.
Results
We found that: (1) HAART resulted in good immune-viral control; (2) the rate of FEV1
decline remained abnormally elevated, even in non-smokers and quitters; and, (3) alcohol
abuse during follow-up was related to FEV1 decline in these patients.
Discussion
Despite adequate immune-viral control by HAART, lung function decline remains increased
in most HIV patients, even in non-smokers and quitters. Alcohol abuse is a preventable risk
factor to decrease the accelerated FEV1 decline in this population.
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Introduction
The rate of lung function decline over time, as determined by changes in the expired volume in
the 1st second of a forced spirometry (FEV1), is increased in patients infected with the human
immunodeficiency virus (HIV) [1–5]. The precise biological mechanisms underlying this observa-
tion are unclear but may include, among others, alterations in cellular immunity due to HIV infec-
tion, presence of chronic airway bacterial colonization due to a defective immune response and/or
increased oxidative stress due to concurrent exposure to tobacco smoking or other toxic sub-
stances (marijuana, cocaine, heroin, alcohol) which are prevalent in this population [1–3], [6–13].
Highly Active Antiretroviral Therapy (HAART) results in very effective immune-viral con-
trol in patients infected with HIV [14]. We hypothesized that, if the enhanced rate of FEV1
decline previously reported in HIV patients was somehow related to the immune derange-
ments caused by HIV, then effective HAART treatment (defined by a viral load < 200 copies/
ml and/or CD4 counts higher than 350 cells/ml [15]) should normalize it, particularly in never
smokers or quitters, since smoking is a well established risk factor for accelerated FEV1 decline
in the general population. We explored this hypothesis in a prospectively recruited cohort of
(smoker and non-smoker) HIV patients effectively treated with HAART, followed up in
Palma de Mallorca (Spain) during 6 years. The cross-sectional characteristics of this cohort at
recruitment have been published before [3].
Methods
Study design and ethics
Fig 1 presents the consort diagram of the study. Briefly, between July 2008 and March 2010,
285 HIV-infected patients signed their informed consent to participate in our cohort; 10 of
them later refused to participate, so we finally included in our first cross-sectional analysis 275
patients [3]. These patients were followed-up regularly (4–6 months) in our clinic every six
months until 2014–2016 (follow-up time 6.1±0.7 years), when those still attending the service
were invited to be studied again. The study was approved by the Ethics Committee of the Bale-
aric Islands, and all participants signed a new informed consent.
Measurements
As reported before [3], symptoms and relevant clinical data were recorded using validated ques-
tionnaires (St. George’s Respiratory Questionnaire (SGRQ) [16] and Modified British Medical
Research Council (mMRC) Questionnaire [17]). Toxic habits including tobacco and marijuana
smoking and systemic drug use were self-reported. Alcohol consumption was measured with
AUDIT test (AUDIT-C [18]). HIV predictors (viral load and quantification of lymphocyte pop-
ulations) were determined in peripheral venous blood laboratories and equipment commonly
used in our center. Forced spirometry and carbon monoxide lung diffusion capacity (DLCO)
were measured (Medisoft Bodybox 5500, Medisoft, Belgium) following international guidelines
[19]. Reference values were those of a Mediterranean population [20,21]. The presence (post-
bronchodilator FEV1/FVC< 0.7) and severity of airflow limitation was established according to
the GOLD criteria [1]. DLCO was corrected for hemoglobin values following standard method-
ology. A DLCO< 80% of the reference value was considered abnormal [22]. The six-minute
walking distance (6-MWD) was determined following international standards [23].
Statistical analysis
Results are expressed as n (%), mean ± SD, or median [25–75 inter-quartile range], as appro-
priate. Unpaired T-test or Mann-Whitney U test were used to compare independent groups,
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whereas the McNemar test, Wilcoxson or paired T-test were used to compare groups at differ-
ent time points. Correlations between continuous variables were explored by the Pearson or
Spearman tests. Multivariable logistic regression analyses were used to explore the Odds Ratio
(OR) of potential risk factors for FEV1 decline. A p value < 0.05 was considered significant.
Statistical analyses were performed using SPSS version 22.0 (IBM, Armonk, NY).
Results
Characteristics of patients at recruitment
We included in this analysis 188 patients, 66% of those included in our original cohort, all of
them with complete follow-up data (S1 Fig). As shown in S1 Table, there were no major demo-
graphic or clinical differences between them and those not included (n = 97;34%) in the cur-
rent analysis.
Fig 1. Box plot comparing the absolute FEV1 annual change in patients with normal (27%) or abnormal (73%) rate of FEV1 decline. For further
explanations, see text.
https://doi.org/10.1371/journal.pone.0224510.g001
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Table 1 presents the main demographic and clinical characteristics of the 188 patients ana-
lyzed here. Most of them (76%) were males with a mean age of 49.2±6.7 years. Most participants
(93%) were of Caucasian origin; the rest were of Latin-American (5%), Asian (1%), Caribbean
(0.5%) or North-African (0.5%) origin. Table 1 also shows their toxic exposures at recruitment.
HIV infection had been diagnosed 13.3±5.0 years before study entry. About a third of par-
ticipants were in asymptomatic CDC stage (CDC-A), another third in stage CDC-B and the
other third in CDC-C (the AIDS defining stage). Most of them (96%) were treated with
HAART and had undetectable viral loads (<50 copies/mL); three patients were considered
“elite controllers” (<50 copies/mL and CD4>500 cell ml-1) and were not treated with
HAART. Median [IQR] CD4+ T cells value at recruitment was 565.5 [394.5–814.8] mL-1. Pre-
vious diagnosis of P. jiroveci pneumonia (9.6%), hepatitis C (35.6%) and tuberculosis (11.7%)
were often reported.
Most participants were asymptomatic and had good health status (SGRQ). On average, spi-
rometry was normal but, 17% of participants had evidence of airflow limitation, which was of
mild (62.5%) or moderate (37.5%) severity. Only 5% of these patients had been previously
diagnosed of COPD and only 30% of them received COPD treatment.
Changes during follow-up
There was a significant reduction in current smoking habits and active cocaine consumption,
but a significant rise in alcohol abuse (Table 1). HAART was indeed quite effective since only 6
patients (3.2%) presented a detectable viral load at the end of follow up and in all of them it
was<200 copies/ml (91.2 [62.3–166.0] copies/ml).
In these well-controlled HIV patients, median FEV1 decline was 55 [28–87] ml/yr which is
higher than the accepted upper limit of normal (30 ml/yr) [1,24]. As a result, the prevalence of
airflow limitation increased from 17% at recruitment to 27% six year later (p<0.001), which at
the end of follow up, was mild in 47% of patients, moderate in 51% and severe in 2%. To iden-
tify what variables were independently associated with FEV1 decline in this cohort, we used
two complementary approaches.
First, we compared the clinical and physiological characteristics, both at recruitment and
after six years follow-up, of patients with an FEV1 decline rate below or above the upper nor-
mal threshold value (30 ml/yr) [1,24] and used multivariable logistic regression analyses to
explore the Odd Ratio (OR) of potential independent risk factors. Second, we considered
changes in FEV1 during follow-up as a continuous variable and used lineal logistic regression
analyses.
Comparison of normal vs. rapid FEV1 decliners
Considering that the upper normal limit of FEV1 decline is 30 ml/yr [1,24], 27% of patients
had a normal FEV1 decline during follow-up (median -14.6 [5.0/-24.0] ml/yr) whereas 73%
showed increased FEV1 decline (median -67.8 [-49.7/-99.2] ml/yr, p<0.0001) (Fig 1). Patients
with abnormal rate of FEV1 decline were more symptomatic (higher SGRQ score) and had
lower FEV1 values at end of follow up (Table 2), albeit it was higher at recruitment. Of note,
smoking exposure or status (never, former or current smoker) was not different in normal and
rapid decliners. Finally, the occurrence of other respiratory diseases, viral load or circulating
CD4 was not different between patients with normal or enhanced rate of FEV1 decline. Of
note, however, alcohol abuse prevalence was higher in rapid decliners, both at recruitment and
end of follow-up (Table 2). Multivariable analysis identified alcohol abuse and initial FEV1 val-
ues as independent factors associated with normal or abnormal FEV1 decline but excluded
smoking exposure or current status at the end of follow-up (Table 3).
FEV1 decline in HIV patients with adequate immune-viral control
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Table 1. Main characteristics (%, mean±SD or median [IQR]) of participants (n = 188) at recruitment and after 6 years follow-up.
RECRUITMENT FOLLOW-UP P value
Demographics
Males 76%
Age. years 49.2±6.7 55.2±6.8 <0.001
BMI. kg/m2 24.0±3.8 24.5±4.0 0.002
HIV data
Years with HIV+ 13.3±5.3 19.2±5.1 <0.001
HAART 95.7% 98.4% 0.063










CD4 nadir . cells mL-1 251 [108–468]
CD4 nadir < 200 cell mL-1 77 (41.0%)
CD4 <200 (month) 2 (0–18)
Viral load zenit . copies/mL 44242 [6997.5–186181]
CD4 cells mL-1 565.5 [394.5–814.75] 648.0 [466.5–888] 0.002
< 200 cell mL-1 6 (3.2%) 5 (2.7%) 0.004
200–350 cell mL-1 26 (13.8%) 18 (9.7%)
350–500 cell mL-1 43 (22.9%) 32 (17.2%)
>500 cell mL-1 113 (60.1%) 131 (70.4%)
CD4/CD8 0.695 [0.44–1.045] 0.915 [0.6275–1.275] <0.001
<0.6 74 (39.4%) 45 (24.2%) <0.001
0.6–0.8 38 (20.2%) 33 (17.7%)






Pack-years 30.8±19 33.7±21 <0.001
Alcohol use 46.3% 70.2% <0.001
Alcohol abuse 4.8% 19.7% <0.001
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Variables associated with absolute FEV1 changes during follow-up
Table 4 presents the list of factors associated with FEV1 decline (when it was considered a con-
tinuous variable and not dichotomized into normal and rapid decliners (see below)). Smoking
exposure, alcohol abuse during follow-up, years of HIV infection and forced vital capacity at
recruitment were identified as independent risk factors of FEV1 decline in this cohort.
Effects of smoking
At the end of follow-up 52.6% of participants were either never (15.4%) or former smokers
(37.2%), whereas 47.3% of them were still active smokers. Table 5 presents the variables that
Table 1. (Continued)
RECRUITMENT FOLLOW-UP P value
Previous diseases
P. jiroveci pneumonia 9.6% 9.6% 1.000
Hepatitis C 35.6% 35.6% 1.000
Tuberculosis 11.7% 11.7% 1.000
Respiratory data






SGRQ. median IQR) 6.7 [2.1–18.2] 7.8 [2.1–17.9] 0.334
FEV1 (postBD). % ref 94.6±13.9 90.2±14.7 <0.001
FVC (postBD). % ref 96.0±12.1 94.3±12.3 0.013
FEV1/FVC (postBD). % 77.7±8.5 74.1±9.0 <0.001
BMI: body mass index; SGRQ: St. George’s Respiratory Questionnaire; mMRC: modified Medical Research Council breathlessness score; FEV1: forced expiratory
volume in 1st second; FVC: forced vital capacity.
https://doi.org/10.1371/journal.pone.0224510.t001
Table 2. Comparison of main demographic, clinical and lung function characteristics (%, mean±SD or median [IQR]) in patients with a normal (<30ml/yr) or
increased (�30ml/yr) rate of FEV1 decline, both at recruitment and end of six years follow-up. Among variables included in Table 1, only those with p value< 0.05 in
the Bivariate analysis are shown.
FEV1 decline < 30 ml/yr FEV1 decline�30 ml/yr p value
n = 50 (27%) n = 138 (73%)









2.7 [1.7–13.9] 8.8 [3.5–19.1] 0.012




Follow-up 95.2±13.5 88.4±14.8 0.005
SGRQ: St. George’s Respiratory Questionnaire.
https://doi.org/10.1371/journal.pone.0224510.t002
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were significantly different between these two groups at the end of follow-up. Main observa-
tions were that, in current smokers, the prevalence of other toxic exposures (alcohol, mari-
juana, cocaine and heroin) was higher, some HIV related variables were different, the
prevalence of comorbidities was surprisingly lower and, not surprisingly, they had more respi-
ratory symptoms and worse lung function. Of note, their FEV1 decline and the proportion of
patients with abnormal FEV1 decline tended to be higher but differences did not achieve sta-
tistical significance (Table 5). In keeping with this, Fig 2 shows that the mean FEV1 trajectories
from baseline to the end of follow-up in participants with normal (left panel) or enhanced
(right panel) rates of FEV1 decline were not influenced by smoking status at the end of follow
up (never (green line), former (yellow line) and current smokers (red line). Of note, within
each group (normal and abnormal FEV1 decline) were not significantly different.
Discussion
The two main findings of this prospective study in HIV patients with good immune-viral con-
trol by HAART were that: (1) FEV1 decline remained increased in about three quarters of
Table 3. Univariate and multivariable analysis of predictive factors of increased rate (�30 ml/yr) of FEV1 decline in HIV patients. Among variables included in
Table 1, only those with p value< 0.05 in the Bivariate analysis are shown.
Univariate analysis Multivariable analysis
Unadjusted OR CI 95% P value Adjusted OR CI 95% P value
Toxic habits
Alcohol abuse follow-up 2.717 0.995–7.422 0.051 3.1883 1.049–9.683 0.041
Respiratory data
FEV1-postBD, % ref. recruitment 1.035 1.007–1.064 0.016 1.030 1.005–1.056 0.019
https://doi.org/10.1371/journal.pone.0224510.t003







BMI (Kg/m2) -0,206 0.005
Toxic habits
Smoker recruitment -0.178 0.015
Pack-years recruitment -0.177 0.026
Pack-years follow-up -0.199 0.015 -0.453 (-0.112/-0,793) 0.010
Alcohol abuse follow-up -0.174 0.017 -20.367 (-2.706/-38.028) 0.024
HIV data
Years with HIV+ -0.125 0.087 -1.53 (-0.156/-2.903) 0.029
Respiratory data
SGRQ total score recruitment -0.195 0.008
SGRQ total score follow-up -0.195 0.007
FVC-postBD (% ref) recruitment -0.270 <0.001 -0.951 (-0.325/-1.576) 0.003
FEV1-postBD (%) recruitment -0.240 0.001
FVC-postBD (% ref) follow-up -0.214 0.003
FEV1-postBD (% ref) follow-up -0.279 <0.001
FEV1/FVC (%) follow-up -0.177 0.015
BMI: body mass index; SGRQ: St. George’s Respiratory Questionnaire; FVC: forced vital capacity.
https://doi.org/10.1371/journal.pone.0224510.t004
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them; and, (2) smoking exposure/status does not seem to play a key pathogenic role, but alco-
hol abuse emerges as an important preventable risk factor.
Previous studies
In the pre-HAART era, the HIV Lung Complications study showed that FEV1 decline was
enhanced in HIV-infected patients followed-up for about 4 years [25]. In the HAART era, the
Table 5. Statistically significant differences between current vs. never and former smokers at the end of follow-up. Variables included in Table 1 not shown here
were not significantly different between these two groups at this time point.
CURRENT SMOKERS NEVER AND FORMER SMOKERS P value
n = 89 (47.3%) n = 99 (52.7%)
Demographic characteristics& toxic exposures
Age in years. mean (SD) 53.3±5.1 57.0±7.7 <0.001
BMI in kg/m2 23.4±3.5 25.5±4.2 <0.001
Pack-years 36 [27–46] 25 [15–35] 0.002
Alcohol abuse 23 (25.8%) 14 (14.1%) 0.044
Marijuana use 34 (38.2%) 8 (8.1%) <0.001
Cocaine use 0.003
Never 33 (37.1%) 63 (63.6%)
Former 51 (57.3%) 30 (30.3%)
Current 5 (5.6%) 6 (6.1%)
Heroine use <0.001
Never 50 (56.2%) 79 (79.8%)
Former 39 (43.8%) 20 (20.2%)
Current 0 (0.0%) 0 (0.0%)
HIV Data
HIV Risk group. n (%) 0.003
Intravenous drugs 37 (41.6%) 20 (20.2%)
Homosexual 27 (30.3%) 39 (39.4%)
Heterosexual 24 (27.0%) 36 (36.4%)
Others 1 (1.1%) 4 (4.0%)
Years with HIV+. mean (SD) 20.1±5.4 18.1±4.7 0.007
CD4 nadir. median (IQR) 301 [187–528] 194 [65–422] 0.003
CD4. median (IQR) 728 [516–912] 598 [429–823] 0.018
CD4 <200 (MONTH) 0 [0–12] 6 [0–20] 0.002
CD4 nadir < 200 24 (27.0%) 53 (53.5%) <0.001
Hepatitis C. n (%) 42 (47.2%) 25 (25.3%) 0.002
Comorbidities
Diabetes. n (%) 6 (6.7%) 16 (16.2%) 0.045
HTA. n (%) 23 (25.8%) 44 (44.4%) 0.008
Respiratory Symptoms & Lung Function
SGRQ. median (IQR) Total 12.6 [5.5–20.9] 4.7 [0.9–10.8] <0.001
FEV1-postBD (%). mean (SD) 87.8±15.4 92.4±13.8 0.030
FEV1/FVC postBD. mean (SD) 71.4±9.19 76.6±8.2 <0.001
DLCO (%). mean (SD) 69.5±12.9 80.1±14.9 <0.001
DLCO <80% 68 (76.4%) 45 (45.5%) <0.001
WT6M (%). mean (SD) 93.32±10.38 104.0±31.3 0.004
FEV1 decline (ml), median (IQR) -61.3 [-97.6;-32.7] -47.8 [-82.7;-25.6] 0.088
FEV1decline> 30 ml/year, n (%) 69 (77.5%) 69 (69.7%) 0.225
https://doi.org/10.1371/journal.pone.0224510.t005
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ALIVE study showed that poorly controlled HIV disease was indeed associated with acceler-
ated lung function decline [26]. Three years later, Kunisaki et al showed that the timing of
HAART initiation did not influence the rate of lung function decline in HIV-positive individ-
uals who were naive to treatment and had CD4+ T-cell counts higher than 500 per μL [27]. A
few months ago, Ronit et al confirmed that HIV infection is indeed associated with low lung
function values and, interestingly, in keeping with our observations here, that this is not
explained by smoking or socioeconomic status and may be mediated by prior immunodefi-
ciency [28]. Our study extends these previous observations by showing that, even in HIV
patients with good immune-viral control due to effective HAART, FEV1 decline is still higher
than normal in the majority (73%) of individuals, including never or former smokers, and
identifies novel and preventable mechanisms underlying this observation, such as alcohol
abuse.
Interpretation of novel findings
In theory, the high rate of FEV1 decline observed in our HIV patients treated with HAART
can be attributed to one or more of the following factors: (1) immune alterations related to
HIV infection [6–8]. At first glance, the fact that FEV1 decline in our cohort was higher than
normal despite good immune-viral control may suggest that immune alterations related to
HIV infection are not a main mechanistic driver. However, there are some subtle caveats that
need careful consideration here. On the one hand, we did not assess directly the potential pul-
monary immune derangements associated to HIV and HAART in these patients so we cannot
exclude that immune-senescence or partial recovery of immunity may still contribute to the
Fig 2. FEV1 trajectories from baseline to end of follow-up in participants with normal (left) or accelerated decliners in addition to the FEV1 changes (right)
stratified by smoking status at the end of follow up (never (green line), former (yellow line) and current smokers (red line). The annualized rates of FEV1
decline within each group were not significantly different. For further explanations, see text.
https://doi.org/10.1371/journal.pone.0224510.g002
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elevated rate of FEV1 decline observed in our patients [29]. In this context, it is of note that
years of HIV infection were indeed identified as significant as a risk factor of FEV1 decline
(Table 3). On the other hand, though, CD4 nadir has been previously associated with emphy-
sema and pulmonary function in people living with HIV [7,28,30], but we were unable to iden-
tify significant differences in FEV1 decline between patients with a CD4 nadir lower or higher
than 200 cell/ml; (2) exposure to tobacco smoking. We found that tobacco smoking was a signif-
icant risk factor for FEV1 decline when it was considered as a continuous variable but not
when patients were dichotomized into normal and rapid decliners (Fig 2). This is in keeping
with the recent observations by Ronit et al who also reported no interaction between HIV and
cumulative smoking [28]. Needless to say, that this should not detract from the importance of
encouraging quitting smoking in the clinic; (3) respiratory infection [9–11, 31]. We did not
observe any significant difference in the previous history of respiratory infections between
patients with normal or accelerated FEV1 decline, suggesting that they were not major patho-
biological players either in this scenario; (4), unexpectedly, we observed that alcohol abuse was
an independent and significant risk factor for the high FEV1 decline seen in this population,
both when FEV1 changes were considered in the analysis as a continuous or dichotomized
variable. The relationship between alcohol abuse and lung function is not well characterized
but there is evidence that it impairs alveolar epithelial surfactant production and barrier integ-
rity, decreases alveolar macrophage function, and renders the lung susceptible to oxidant-
mediated injury [32]. In fact, epidemiological studies have shown that heavy drinkers have
more symptoms of chronic bronchitis than non-heavy drinkers, even after adjusting for smok-
ing exposure, suggesting that heavy drinking has an independent additive negative effect on
lung function in smokers [33]; and, finally (5) it is of note also that a better initial lung function
was also independently associated with a higher rate of FEV1 decline (Table 2). This is known
as “the horse-racing effect of lung function” [34], and has been well described in other non-
infected HIV populations, where those with higher initial FEV1 values are those who lose
more during follow-up [35,36].
Clinical implications
Our study is purely observational and does not include any therapeutic intervention, so it does
not have direct clinical implications. However, we would like to speculate with some potential
implications for clinical practice. First, given the high prevalence and incidence of respiratory
abnormalities observed in HIV infected patients despite being effectively treated with HAART
(Fig 1), we suggest that lung function should be monitored in the clinic routinely in order to
offer these patients specific respiratory treatment if needed. And, secondly, the abandonment
of smoking habits and the abuse of other drugs in this population (as, no doubt, in any other)
should be reinforced. However, given the results discussed above, alcohol abuse deserves par-
ticular therapeutic attention in HIV-infected patients.
Potential limitations
A potential limitation of our study is that we did not include a control group. Yet, what this
control group should be is not straightforward. The ideal comparator would be a group of
untreated HIV infected patients. Obviously, this is not possible because it would be unethical
to withhold treatment to these patients. An alternative can be the use of uninfected individuals
as controls, as recently reported by Ronit et al [28]. Strictly speaking, however, this strategy
compares two different groups of individuals (infected vs. healthy). A third alternative, which
is the one we used here, is to compare our results in current and former/never smokers as well
as to contrast them with those previously reported in the literature in the general population.
FEV1 decline in HIV patients with adequate immune-viral control
PLOS ONE | https://doi.org/10.1371/journal.pone.0224510 October 29, 2019 10 / 13
Another limitation could be to make the study in a single-center, and there may be environ-
mental changes that affect the decline of these patients, and cannot be verified in an uninfected
population. Also, one potential bias in our study is due to missing data. After checking the
database, we found that data was only missing from the outcome variable so we decided to use
a complete case analysis following recent evidence.
Conclusions
Despite adequate immune-viral control by HAART, the rate of FEV1 decline remains elevated
in a majority of HIV patients. Smoking does not appear to be the main driver of this observa-
tion but alcohol abuse emerges as a novel, important, and preventable, risk factor.
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